Skip to main content
SpringerLink
Log in

Neuroimaging Modalities in Neuroimmunology

  • Chapter
  • First Online:
Neuroimmunology

  • 1490 Accesses

Abstract

Magnetic resonance imaging (MRI) plays a central role in the diagnostic workup and clinical management of neuroimmunological diseases, including multiple sclerosis (MS). MRI is highly sensitive to visualize white matter signal abnormalities on T2-weighted images, and the characteristic appearance of demyelinating lesions has become well recognized. However, MRI is not pathologically specific, and differentiating MS from other (non-MS) conditions remains a challenge in the field. This chapter reviews the role of MRI in diagnosing and monitoring MS patients over time and discusses promising MR techniques that may increase the specificity of MRI for demyelination, including central vein imaging and cortical lesion detection, to help distinguish MS from other diagnoses. We also discuss possible applications of volumetric MRI as a way to monitor patients over time, and we highlight positron emission tomography (PET) methods that have been used in MS and may further our understanding of the biology of the disease, with particular focus on PET measures of microglial activation and remyelination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.

    Article  PubMed  Google Scholar 

  3. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.

    Article  CAS  PubMed  Google Scholar 

  4. Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DKB, McDonald WI, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 1999;53(3):448–56.

    Article  CAS  PubMed  Google Scholar 

  5. Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11(4):349–60.

    Article  PubMed  Google Scholar 

  6. Filippi M. Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler. 2000;6(5):320–6.

    Article  CAS  PubMed  Google Scholar 

  7. Cotton F, Weiner HL, Jolesz FA, Guttmann CRG. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003;60(4):640–6.

    Article  PubMed  Google Scholar 

  8. Lassmann H. A dynamic view of the blood-brain barrier in active multiple sclerosis lesions. Ann Neurol. 2011;70(1):1–2.

    Article  PubMed  Google Scholar 

  9. Gaitán MI, Shea CD, Evangelou IE, Stone RD, Fenton KM, Bielekova B, et al. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol. 2011;70(1):22–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Van Der Vuurst De Vries RM, Mescheriakova JY, YYM W, Runia TF, Jafari N, Samijn JP, et al. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol. 2018;75(11):1392–8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Geurts JJG, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology. 2011;76(5):418–24.

    Article  CAS  PubMed  Google Scholar 

  12. Seewann A, Kooi EJ, Roosendaal SD, Pouwels PJW, Wattjes MP, Van Der Valk P, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology. 2012;78(5):302–8.

    Article  CAS  PubMed  Google Scholar 

  13. Sethi V, Muhlert N, Ron M, Golay X, Wheeler-Kingshott CA, Miller DH, et al. MS cortical lesions on DIR: not quite what they seem? PLoS One. 2013;8(11):8–12.

    Article  CAS  Google Scholar 

  14. Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, et al. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology. 2016;87(13):1393–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017;13(9):567–72.

    Article  PubMed  Google Scholar 

  16. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800–5.

    Article  CAS  PubMed  Google Scholar 

  17. Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014;9(3):e90509.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann Neurol. 2016;79(2):288–94.

    Article  PubMed  Google Scholar 

  19. Sati P, Oh J, Todd Constable R, Evangelou N, Guttmann CRG, Henry RG, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the north American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714–22.

    Article  PubMed  Google Scholar 

  20. Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edinburgh. 1916;50(03):517–740.

    Article  Google Scholar 

  21. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13.

    Google Scholar 

  22. Metcalf M, Xu D, Okuda DT, Carvajal L, Srinivasan R, Kelley DAC, et al. High-resolution phased-array MRI of the human brain at 7 Tesla: Initial experience in multiple sclerosis patients. J Neuroimaging 2010;20:141–47.

    Article  PubMed  Google Scholar 

  23. Sati P, George IC, Shea CD, Gaitán MI, Reich DS. FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. Radiology. 2012;265(3):926–32.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tallantyre EC, Brookes MJ, Dixon JE, Morgan PS, Evangelou N, Morris PG. Demonstrating the perivascular distribution of MS lesions in vivo with 7-tesla MRI. Neurology. 2008;70(22):2076–9.

    Article  CAS  PubMed  Google Scholar 

  25. Mistry N, Dixon J, Tallantyre E, Tench C, Abdel-Fahim R, Jaspan T, et al. Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. JAMA Neurol. 2013;70(5):623–8.

    Article  PubMed  Google Scholar 

  26. Sparacia G, Agnello F, Gambino A, Sciortino M, Midiri M. Multiple sclerosis: high prevalence of the ‘central vein’ sign in white matter lesions on susceptibility-weighted images. Neuroradiol J. 2018;31(4):356–61.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lumsden C. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn G, editors. Handbook of clinical neurology. Amsterdam: Elsevier; 1970. p. 217–309.

    Google Scholar 

  28. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68(22 Supp):S22–31.

    Article  PubMed  Google Scholar 

  29. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–93.

    Article  CAS  PubMed  Google Scholar 

  30. Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, et al. Imaging cortical lesions in multiple sclerosis with ultra–high-field magnetic resonance imaging. Arch Neurol. 2010;67(7):812–8.

    Article  PubMed  Google Scholar 

  31. Kilsdonk ID, Jonkman LE, Klaver R, Van Veluw SJ, Zwanenburg JJM, Kuijer JPA, et al. Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain. 2016;139(5):1472–81.

    Article  PubMed  Google Scholar 

  32. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669–76.

    Article  PubMed  Google Scholar 

  33. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(3):808–17.

    Article  CAS  PubMed  Google Scholar 

  34. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236–42.

    Article  PubMed  Google Scholar 

  35. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009;65(3):268–75.

    Article  PubMed  Google Scholar 

  36. Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler J 2011;17(5):541–549.

    Google Scholar 

  37. Traboulsee A, Létourneau-Guillon L, Freedman MS, O’Connor PW, Bharatha A, Chakraborty S, et al. Canadian expert panel recommendations for MRI use in MS diagnosis and monitoring. Can J Neurol Sci. 2015;42(3):159–67.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Consortium of MS centers MRI protocol and clinical guidelines for the diagnosis and follow-up of MS: 2018 Revised Guidelines [Internet]. Available from: www.mscare.org/mri

  39. Moraal B, Wattjes MP, Geurts JJG, Knol DL, van Schijndel RA, Pouwels PJW, et al. Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology. 2010 Apr;255(1):154–63.

    Article  PubMed  Google Scholar 

  40. Moraal B, Van Den Elskamp IJ, Knol DL, Uitdehaag BMJ, Geurts JJG, Vrenken H, et al. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Ann Neurol. 2010;67(5):667–75.

    PubMed  Google Scholar 

  41. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:150025.

    Article  Google Scholar 

  42. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278–85.

    Article  CAS  PubMed  Google Scholar 

  43. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206(2):165–71.

    Article  CAS  PubMed  Google Scholar 

  44. De Stefano N, Airas L, Grigoriadis N, Mattle HP, O’Riordan J, Oreja-Guevara C, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28(2):147–56.

    Article  PubMed  Google Scholar 

  45. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5(2):158–70.

    Article  PubMed  Google Scholar 

  46. Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, et al. The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci. 2015;357(1–2):8–18.

    Article  PubMed  Google Scholar 

  47. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412–20.

    Article  CAS  PubMed  Google Scholar 

  48. Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner IK, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14(3):302–417.

    Article  PubMed  Google Scholar 

  49. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009;72(20):1760–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, et al. Phase 2 trial of Ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nakamura K, Brown RA, Narayanan S, Collins DL, Arnold DL. Diurnal fluctuations in brain volume: statistical analyses of MRI from large populations. NeuroImage. 2015;118:126–32.

    Article  PubMed  Google Scholar 

  52. Nakamura K, Brown RA, Araujo D, Narayanan S, Arnold DL. Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: implications for monitoring atrophy in clinical studies. NeuroImage Clin. 2014;6:166–70.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390–401.

    Article  CAS  PubMed  Google Scholar 

  54. Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol NeuroInflamm. 2015;2(3):e102.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008;79(11):1236–44.

    Article  CAS  PubMed  Google Scholar 

  56. Aubert-Broche B, Fonov V, Ghassemi R, Narayanan S, Arnold DL, Banwell B, et al. Regional brain atrophy in children with multiple sclerosis. NeuroImage. 2011;58(2):409–15.

    Article  CAS  PubMed  Google Scholar 

  57. Henry RG, Shieh M, Amirbekian B, Chung SW, Okuda DT, Pelletier D. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci. 2009;282(1–2):61–6.

    Article  PubMed  Google Scholar 

  58. Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, et al. Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018;83(2):223–34.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. Am J Neuroradiol. 2013;34(10):1931–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Houtchens MK, Benedict RHB, Killiany R, Sharma J, Jaisani Z, Singh B, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007;69(12):1213–23.

    Article  CAS  PubMed  Google Scholar 

  61. Rocca MA, Battaglini M, Benedict RHB, De Stefano N, Geurts JJG, Henry RG, et al. Brain MRI atrophy quantification in MS. Neurology. 2017;88(4):403–13.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Azevedo CJ, Pelletier D. Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? Curr Opin Neurol. 2016;29(3):237–42.

    Article  CAS  PubMed  Google Scholar 

  63. De Stefano N, Stromillo ML, Giorgio A, Bartolozzi ML, Battaglini M, Baldini M, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(1):93–9.

    PubMed  Google Scholar 

  64. Moccia M, Ciccarelli O. Molecular and metabolic imaging in multiple sclerosis. Neuroimaging Clin N Am. 2017;27(2):343–56.

    Article  PubMed  Google Scholar 

  65. De Paula Faria D, Copray S, Buchpiguel C, Dierckx R, De Vries E. PET imaging in multiple sclerosis. J Neuroimmune Pharmacol. 2014;9(4):468–82.

    Article  Google Scholar 

  66. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35(3):306–28.

    Article  CAS  PubMed  Google Scholar 

  67. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(5):1175–89.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135(3):886–99.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Doble A, Malgouris C, Daniel M, Daniel N, Imbault F, Basbaum A, et al. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull. 1987;18(1):49–61.

    Article  CAS  PubMed  Google Scholar 

  70. Airas L, Nylund M, Rissanen E. Evaluation of microglial activation in multiple sclerosis patients using positron emission tomography. Front Neurol. 2018;9:181.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Dickens AM, Vainio S, Marjamaki P, Johansson J, Lehtiniemi P, Rokka J, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med. 2014;55(3):466–72.

    Article  CAS  PubMed  Google Scholar 

  72. Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A. Kinetic modeling without accounting for the vascular component impairs the quantification of [11C]PBR28 brain PET data. J Cereb Blood Flow Metab. 2014;34(6):1060–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. 2003;10(3):257–64.

    Article  CAS  PubMed  Google Scholar 

  74. Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, et al. 11C–PBR28 imaging in multiple sclerosis patients and healthy conrols: test-retest reproducibility and focual visualization of active white matter areas. Eur J Nucl Med Mol Imaging 2015;42:1081–92.

    Google Scholar 

  75. Rissanen E, Tuisku J, Rokka J, Paavilainen T, Parkkola R, Rinne JO, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med. 2014;55(6):939–44.

    Article  CAS  PubMed  Google Scholar 

  76. Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med. 2017;58(10):1646–51.

    Article  CAS  PubMed  Google Scholar 

  77. Herranz E, Giannì C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016;80(5):776–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Narayan N, Mandhair H, Smyth E, Dakin SG, Kiriakidis S, Wells L, et al. The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory ‘M1’ human macrophages. PLoS One. 2017;12(10):1–19.

    Article  CAS  Google Scholar 

  79. Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, et al. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab. 2017;37(8):2679–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Wu C, Tian D, Feng Y, Polak P, Wei J, Sharp A, et al. A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem. 2011;54(9):997–1004.

    Article  CAS  Google Scholar 

  81. De Paula Faria D, Copray S, Sijbesma JW, Willemsen AT, Buchpiguel CA, Dierckx RA, et al. PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C]MeDAS, [11C]CIC and [11C]PIB. Eur J Nucl Med Mol Imaging. 2014;41(5):995–1003.

    Article  Google Scholar 

  82. Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol. 2016;79(5):726–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint Louis University School of Medicine, Saint Louis, MO, USA

    Lokesh A. Rukmangadachar

  2. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Christina J. Azevedo

Authors
  1. Lokesh A. Rukmangadachar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina J. Azevedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina J. Azevedo .

Editor information

Editors and Affiliations

  1. University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    Amanda L. Piquet

  2. University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    Enrique Alvarez

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rukmangadachar, L.A., Azevedo, C.J. (2021). Neuroimaging Modalities in Neuroimmunology. In: Piquet, A.L., Alvarez, E. (eds) Neuroimmunology. Springer, Cham. https://doi.org/10.1007/978-3-030-61883-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-61883-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-61882-7

  • Online ISBN: 978-3-030-61883-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation